Cabaletta Bio (CABA) Share-based Compensation (2018 - 2026)
Cabaletta Bio (CABA) posted quarterly Share-based Compensation of $4.3 million for Q4 2025, up 237.75% year-over-year from $1.3 million in Q4 2024, and down 88.99% quarter-over-quarter from $38.7 million in Q3 2025.
Cabaletta Bio (CABA) Share-based Compensation (2018 - 2026) Analysis & Trends
Cabaletta Bio's Share-based Compensation history runs 8 years deep, the most recent figure standing at $4.3 million for Q4 2025.
- In Q4 2025, Share-based Compensation rose 237.75% year-over-year to $4.3 million; the TTM figure through Dec 2025 stood at $9.1 million (up 334.22% YoY), while the FY2025 annual figure was $20.9 million, up 91.0% from the prior year.
- Share-based Compensation for Q4 2025 stood at $4.3 million, down from $38.7 million in the prior quarter.
- The five-year high for Share-based Compensation was $47.4 million in Q2 2025, with the low at -$6.2 million in Q4 2023.
- The 5-year median for Share-based Compensation is $1.6 million (2021), against an average of $5.7 million.
- The sharpest annual moves came in 2023 and 2024: Share-based Compensation plunged 495.69% in 2023, then soared 173535.06% in 2024.
- Cabaletta Bio's Share-based Compensation stood at $1.6 million in 2021, then fell by 1.44% to $1.6 million in 2022, then slumped by 495.69% to -$6.2 million in 2023, then jumped by 50.5% to -$3.1 million in 2024, then soared by 237.75% to $4.3 million in 2025.
- Business Quant data shows CABA's Share-based Compensation at $4.3 million in Q4 2025, $38.7 million in Q3 2025, and $47.4 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Cabaletta Bio | 466.25 Mn | 466.25 Mn | - | 35.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 35.49 Mn |
| Jun 30, 2026 | 35.49 Mn |
| Dec 31, 2025 | 4.26 Mn |
| Dec 31, 2025 | 4.26 Mn |
| Sep 30, 2025 | 38.66 Mn |
| Sep 30, 2025 | 38.66 Mn |
| Jun 30, 2025 | 47.43 Mn |
| Jun 30, 2025 | 47.43 Mn |
| Mar 31, 2025 | 5.16 Mn |
| Mar 31, 2025 | 5.16 Mn |
| Dec 31, 2024 | -3.09 Mn |
| Dec 31, 2024 | -3.09 Mn |
| Sep 30, 2024 | 2.77 Mn |
| Sep 30, 2024 | 2.77 Mn |
| Jun 30, 2024 | 2.42 Mn |
| Jun 30, 2024 | 2.42 Mn |
| Dec 31, 2023 | -6.24 Mn |
| Dec 31, 2023 | -6.24 Mn |
| Sep 30, 2023 | 1,596.00 |
| Sep 30, 2023 | 1,596.00 |